Results · Apr-Jun 2026
Panacea Biotec Q1 FY27 results
Sales grew 20% to ₹200 crore from ₹167 crore in Apr-Jun 2025.
Operating profit was ₹5.7 crore, an operating margin of 2.8% (up 3.5 points from a year ago).
Net profit fell 44% to ₹2.2 crore from ₹4 crore in Apr-Jun 2025.
Against Jan-Mar 2026: sales +20%, net profit turns positive.
Apr-Jun 2026 vs a year ago
| ₹ crore | Apr-Jun 2026 | Apr-Jun 2025 | Change |
|---|---|---|---|
| Sales | 199.6 | 166.7 | +20% |
| Operating profit (EBITDA) | 5.7 | -1.2 | n/m |
| Operating margin | 2.8% | −0.7% | +3.5 pts |
| Net profit | 2.2 | 4.0 | −44% |
Consolidated figures. Margins & ratios change in percentage points (pts).
The last 7 quarters
From the company's results filed on BSE (Consolidated). Business numbers only. Education & analysis, not investment advice or a recommendation.